DICE Therapeutics stockholders approve officer exculpation amendment, elect directors

On June 7, 2023, at the Annual Meeting of Stockholders (the “ Annual Meeting ”) of DICE Therapeutics, Inc. (the “ Company ”), the Company’s stockholders approved an amended and restated certificate of incorporation (the “ Amended and Restated Certificate of Incorporation ”) to permit the exculpation of the Company’s officers from liability in certain circumstances. On June 7, 2023, the Company filed with the Secretary of State of the State of Delaware the Amended and Restated Certificate of Incorporation.

Proposal No. 1 – Election of Class II Directors The Company’s stockholders elected the two Class II director nominees to the Company’s Board of Directors for a term of three years expiring with respect to each director at the annual meeting of stockholders to be held in 2026 and until such director’s successor is duly elected and qualified or until such director’s earlier resignation or removal, with the votes cast as follows: Nominee Votes For Votes Withheld Broker Non-Votes Jim Scopa 32,540,055 9,054,159 3,655,517 Jake Simson, Ph.D. 32,596,683 8,997,531 3,655,517

Proposal No. 2 – Ratification of Independent Registered Public Accounting Firm The Company’s stockholders ratified the selection of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2023, with the votes cast as follows: Votes For Votes Against Votes Withheld Broker Non-Votes 45,245,715 3,113 903 —

Proposal No. 3 – Approval of an Amended and Restated Certificate of Incorporation to permit the Exculpation of Officers The Company’s stockholders approved the Amended and Restated Certificate of Incorporation to permit the exculpation of officers in certain circumstances, with the votes cast as follows: Votes For Votes Against Votes Withheld Broker Non-Votes 40,311,115 1,282,156 943 3,655,517